Advertisement
The Inflammatory Bowel Disease Disability Index for self-report is reliable and valid for measuring disability in inflammatory bowel disease

IBD Disability Index for Self-Report Reliable, Valid

0
Item-reduced version with eight questions instead of 28 accounted for 77 percent of variance
The U.S. Food and Drug Administration on Friday announced it has approved Aemcolo (rifamycin)

FDA Approves Drug for Treatment of Travelers’ Diarrhea

0
Aemcolo not indicated for patients with diarrhea complicated by fever and/or bloody stool
The U.S. Food and Drug Administration and U.S. Centers for Disease Control and Prevention along with health officials from various states are asking American consumers to avoid romaine lettuce due to an outbreak of Escherichia coli illness.

FDA: Another E. coli Outbreak Linked to Romaine Lettuce

0
So far, 32 people across 11 states have become sick with E. coli after eating romaine lettuce
The prevalence of food allergy is 7.6 percent among children in the United States

Prevalence of Food Allergy 7.6 Percent in U.S. Children

0
Most prevalent allergens are peanut, milk, shellfish, and tree nut
Men and women who are obese as adolescents are at an increased risk for pancreatic cancer in adulthood

Obesity as a Teen Ups Risk for Later Pancreatic Cancer

0
In men, overweight and even higher normal weight tied to increased risk
Almost 2 percent of children in the United States have a milk allergy

ACAAI: Almost 2 Percent of Children Have Milk Allergy

0
Among children with food allergy, 53 percent of infants have milk allergy vs. 15 percent of teens
In the first six months of 2018

CDC: 8.8 Percent Uninsured in U.S. in First Half of 2018

0
12.5 percent of adults aged 18-64 years and 4.4 percent of children aged 0-17 years uninsured
Both hospitalizations and deaths are increasing among Medicare recipients with liver cancer

Burden of Liver Cancer Rising in Medicare Patients

0
Coexistence of other liver conditions tied to even higher risk for death, health care costs
Combined treatment with glecaprevir and pibrentasvir is highly effective in treating chronic hepatitis C virus genotype-1 infections that failed to respond to direct-acting antiviral therapy

Option Found for Retreatment of Chronic Hep C Infection

0
Glecaprevir + pibrentasvir effective for those who previously failed direct-acting antiviral treatment
Patients with uncomplicated appendicitis undergoing nonoperative management are more likely to have an appendicitis-associated readmission and to develop an abscess

Harms ID’d With Nonoperative Management of Appendicitis

0
Higher likelihood of readmission, developing abscess; more follow-up needed in year after admission